Drug intelligence / Profile preview

Mito Q7

Development stage: Unknown
Lead developer: Bion Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

Mito Q7 is a nutraceutical formulation developed and marketed by Bion Therapeutics India Pvt Ltd. It is designed to provide mitochondrial and antioxidant support, primarily for managing metabolic disorders and vitamin deficiencies. The formulation contains a combination of Ubidecarenone (Coenzyme Q10), L-carnitine, Benfotiamine (a lipid-soluble derivative of Vitamin B1), Riboflavin (Vitamin B2), Pyridoxine Hydrochloride (Vitamin B6), and Ascorbic acid (Vitamin C). These ingredients work synergistically to enhance cellular energy production, reduce oxidative stress, and improve symptoms associated with conditions like diabetic neuropathy and general fatigue. It is available as an oral tablet and is marketed as a health supplement in India.

Brand names: Mito Q7
Other names: MitoQ7MitoQ-7MitoQ 7

Beyond the preview

Go deeper on Mito Q7.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mito Q7.

Explore the full profile